PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.92%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-17.46%
Negative gross profit growth while CRON.TO is at 30.21%. Joel Greenblatt would examine cost competitiveness or demand decline.
-31.73%
Negative EBIT growth while CRON.TO is at 0.72%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-31.73%
Negative operating income growth while CRON.TO is at 6.26%. Joel Greenblatt would press for urgent turnaround measures.
6.32%
Net income growth under 50% of CRON.TO's 56.59%. Michael Burry would suspect the firm is falling well behind a key competitor.
16.67%
EPS growth under 50% of CRON.TO's 56.72%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
9.09%
Diluted EPS growth under 50% of CRON.TO's 56.72%. Michael Burry would worry about an eroding competitive position or excessive dilution.
8.22%
Share count expansion well above CRON.TO's 0.09%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.33%
Diluted share count expanding well above CRON.TO's 0.09%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
163.13%
OCF growth above 1.5x CRON.TO's 75.31%. David Dodd would confirm a clear edge in underlying cash generation.
150.08%
FCF growth above 1.5x CRON.TO's 74.69%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
314.91%
5Y revenue/share CAGR 1.25-1.5x CRON.TO's 239.61%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
-45.00%
Negative 3Y CAGR while CRON.TO stands at 75.16%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
8257.32%
OCF/share CAGR of 8257.32% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
66.67%
Positive OCF/share growth while CRON.TO is negative. John Neff might see a comparative advantage in operational cash viability.
133.03%
3Y OCF/share CAGR above 1.5x CRON.TO's 72.02%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-1627.18%
Negative 10Y net income/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-333.74%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-256.42%
Negative 3Y CAGR while CRON.TO is 92.89%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
7683.64%
Equity/share CAGR of 7683.64% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
181.95%
5Y equity/share CAGR at 75-90% of CRON.TO's 203.88%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
18.65%
Positive short-term equity growth while CRON.TO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.79%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-1.52%
Inventory is declining while CRON.TO stands at 2.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.11%
Negative asset growth while CRON.TO invests at 0.76%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-9.22%
We have a declining book value while CRON.TO shows 0.83%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-7.43%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-0.60%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
4.40%
SG&A growth well above CRON.TO's 1.33%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.